Philipp E Hartrampf
Overview
Explore the profile of Philipp E Hartrampf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
261
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heinrich M, Blickle E, Hartrampf P, Hasenauer N, Kosmala A, Kerscher A, et al.
Eur J Nucl Med Mol Imaging
. 2025 Mar;
PMID: 40088267
Purpose: The aim of this study is to investigate the impact of lymph node metastases (LNM) detected on cervical I single photon emission computed tomography/computed tomography (SPECT/CT) after the first...
2.
Zhi Y, Serfling S, Groener D, Hartrampf P, Higuchi T, Scheich M, et al.
Clin Nucl Med
. 2025 Mar;
PMID: 40025672
Background: We aim to report on somatostatin receptor (SSTR)-targeted molecular imaging and therapy in patients with advanced esthesioneuroblastoma (ENB). Patients And Methods: Five patients with ENB [Kadish stage D in...
3.
Kosmala A, Hasenauer N, Serfling S, Michalski K, Frohlich M, Dreher N, et al.
Theranostics
. 2025 Jan;
15(3):804-814.
PMID: 39776816
To establish the extent, distribution and frequency of in-vivo vessel wall [Ga]Ga-PentixaFor uptake and to determine its relationship with calcified atherosclerotic plaque burden (CAP) and cardiovascular risk factors (CVRF). 65...
4.
Michalski K, Kosmala A, Hartrampf P, Heinrich M, Serfling S, Schlotelburg W, et al.
J Nucl Med
. 2024 Oct;
65(12):1899-1903.
PMID: 39477500
We aimed to quantitatively investigate the prognostic value of PET-based biomarkers on [F]FDG and [Ga]Ga-fibroblast activation protein inhibitor (FAPI)-04 PET/CT in patients with highly aggressive neuroendocrine neoplasms (NENs) and to...
5.
Schloetelburg W, Hartrampf P, Kosmala A, Serfling S, Dreher N, Schirbel A, et al.
Eur J Nucl Med Mol Imaging
. 2024 Jun;
51(12):3643-3650.
PMID: 38896128
Background: In patients affected with adrenocortical carcinoma (ACC), C-X-C motif chemokine receptor 4 (CXCR4) is highly expressed in sites of disease in an ex-vivo setting. We aimed to determine the...
6.
Schumann S, Scherthan H, Hartrampf P, Goring L, Buck A, Port M, et al.
Int J Mol Sci
. 2024 May;
25(10).
PMID: 38791531
This work reports on a model that describes patient-specific absorbed dose-dependent DNA damage response in peripheral blood mononuclear cells of thyroid cancer patients during radioiodine therapy and compares the results...
7.
Hartrampf P, Serfling S, Higuchi T, Bojunga J, Weich A, Werner R
Radiologie (Heidelb)
. 2024 May;
64(7):536-545.
PMID: 38777918
Background: Neuroendocrine neoplasms (NEN) are heterogenous with an increasing incidence in recent years. Objectives: Overview on incidence, symptoms, diagnostics, grading, imaging and prognostic determinants, including factors having an impact on...
8.
Hartrampf P, Huttmann T, Seitz A, Kubler H, Serfling S, Higuchi T, et al.
J Nucl Med
. 2024 Mar;
65(4):560-565.
PMID: 38453363
In metastatic castration-resistant prostate cancer (mCRPC) patients treated with prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), the recently proposed criteria for evaluating response to PSMA PET (RECIP 1.0) based on...
9.
Schlotelburg W, Hartrampf P, Kosmala A, Fuss C, Serfling S, Buck A, et al.
Endocrine
. 2024 Feb;
84(3):1172-1181.
PMID: 38381353
Purpose: We aimed to evaluate the prognostic potential of baseline [F]FDG PET/CT for overall survival (OS) in patients with adrenocortical carcinoma (ACC). Methods: We performed a retrospective analysis of 67...
10.
Michalski K, Schlotelburg W, Hartrampf P, Kosmala A, Buck A, Hahner S, et al.
Pharmaceuticals (Basel)
. 2024 Jan;
17(1).
PMID: 38256859
Adrenocortical carcinoma (ACC) represents a rare tumor entity with limited treatment options and usually rapid tumor progression in case of metastatic disease. As further treatment options are needed and ACC...